Should these results hold up in randomized controlled trials, Dr. Gabriele Simonini
told Reuters Health by email "we then may well choose" adalimumab over infliximab.
In particular, as infliximab requires intravenous administration and hospitalization.
added "This strategy would result in better patient compliance and in a longer efficacy, without losing the therapeutic efficacy and the optimal current standard of care in this therapeutic setting."
In a November 15th on-line paper in Arthritis Care and Research, Dr. Simonini of the University of Florence and colleagues note that tumor necrosis factor alpha blocking agents have been successfully used to treat the disease.